1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cell Therapy Technologies Market
4. Market Overview
    4.1. Introduction
        4.1.1. Market Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Cell Therapy Technologies Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Technological Advancements
    5.2. Overview of Cell Therapy Product Manufacturing Technologies
    5.3. List of Instruments and Consumables Used For Each of the Technologies
    5.4. Key Mergers & Acquisitions
    5.5. Top 3 Players Operating in the Market Space
6. Global Cell Therapy Technologies Market Analysis and Forecast, by Cell Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Cell Type, 2017-2031
        6.3.1. Allogeneic
            6.3.1.1. Blood Cells
            6.3.1.2. Others
        6.3.2. Autologous
            6.3.2.1. Human Embryonic Stem Cells
            6.3.2.2. Hematopoietic Stem Cells
            6.3.2.3. Mesenchymal Stem Cells
            6.3.2.4. Others
    6.4. Market Attractiveness Analysis, by Cell Type
7. Global Cell Therapy Technologies Market Analysis and Forecast, by Product
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Product, 2017-2031
        7.3.1. Tissue Digestion
            7.3.1.1. Instrumentation
            7.3.1.2. Consumables & Reagents
        7.3.2. Cell Selection/ Cell Isolation
            7.3.2.1. Instrumentation
            7.3.2.2. Consumables & Reagents
        7.3.3. Cell Viability Testing
            7.3.3.1. Instrumentation
            7.3.3.2. Consumables & Reagents
        7.3.4. Cell Transduction / Transfection
            7.3.4.1. Instrumentation
            7.3.4.2. Consumables & Reagents
        7.3.5. Cell Expansion
            7.3.5.1. Instrumentation
            7.3.5.2. Consumables & Reagents
        7.3.6. Quality Control Testing
            7.3.6.1. Instrumentation
            7.3.6.2. Consumables & Reagents
    7.4. Market Attractiveness Analysis, by Product
8. Global Cell Therapy Technologies Market Analysis and Forecast, by Technology/Method
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Technology/Method, 2017-2031
        8.3.1. Tissue Digestion
        8.3.2. Cell Selection/Cell Isolation
            8.3.2.1. Immunomagnetic Cell separation (IMS)
            8.3.2.2. Fluorescence-activated Cell Sorting(FACS)
            8.3.2.3. Density Gradient Centrifugation
            8.3.2.4. Microfluidic Cell Separation (MCS)
            8.3.2.5. Others
        8.3.3. Cell Viability Testing
            8.3.3.1. Tetrazolium Reduction Assay
            8.3.3.2. Protease Viability Marker Assay
            8.3.3.3. ATP Assay
            8.3.3.4. Real-Time Assay
            8.3.3.5. Others
        8.3.4. Cell Transduction/Transfection
            8.3.4.1. Cationic-lipid Mediated Transfection
            8.3.4.2. Calcium Phosphate Transfection
            8.3.4.3. Viral Transfection
            8.3.4.4. Electroporation
            8.3.4.5. Others
        8.3.5. Cell Expansion
            8.3.5.1. 3D Cell Culture
            8.3.5.2. Roller Bottle Culture
            8.3.5.3. Cell Culture Scale-up Systems
            8.3.5.4. Spinner Flask Culture
            8.3.5.5. Others
        8.3.6. Quality Control Testing
            8.3.6.1. Endotoxin
            8.3.6.2. Mycoplasma
            8.3.6.3. Others
    8.4. Market Attractiveness Analysis, by Technology/Method
9. Global Cell Therapy Technologies Market Analysis and Forecast, by Application
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by Application, 2017-2031
        9.3.1. Cancer
        9.3.2. Autoimmune Diseases
        9.3.3. Cardiovascular Disorders
        9.3.4. Orthopedic Disorders
        9.3.5. Others
    9.4. Market Attractiveness Analysis, by Application
10. Global Cell Therapy Technologies Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America Cell Therapy Technologies Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Cell Type, 2017-2031
        11.2.1. Allogeneic
            11.2.1.1. Blood Cells
            11.2.1.2. Others
        11.2.2. Autologous
            11.2.2.1. Human Embryonic Stem Cells
            11.2.2.2. Hematopoietic Stem Cells
            11.2.2.3. Mesenchymal Stem Cells
            11.2.2.4. Others
    11.3. Market Value Forecast, by Product, 2017-2031
        11.3.1. Tissue Digestion
            11.3.1.1. Instrumentation
            11.3.1.2. Consumables & Reagents
        11.3.2. Cell Selection/ Cell Isolation
            11.3.2.1. Instrumentation
            11.3.2.2. Consumables & Reagents
        11.3.3. Cell Viability Testing
            11.3.3.1. Instrumentation
            11.3.3.2. Consumables & Reagents
        11.3.4. Cell Transduction / Transfection
            11.3.4.1. Instrumentation
            11.3.4.2. Consumables & Reagents
        11.3.5. Cell Expansion
            11.3.5.1. Instrumentation
            11.3.5.2. Consumables & Reagents
        11.3.6. Quality Control Testing
            11.3.6.1. Instrumentation
            11.3.6.2. Consumables & Reagents
    11.4. Market Value Forecast, by Technology/Method, 2017-2031
        11.4.1. Tissue Digestion
        11.4.2. Cell Selection/Cell Isolation
            11.4.2.1. Immunomagnetic Cell separation (IMS)
            11.4.2.2. Fluorescence-activated Cell Sorting(FACS)
            11.4.2.3. Density Gradient Centrifugation
            11.4.2.4. Microfluidic Cell Separation (MCS)
            11.4.2.5. Others
        11.4.3. Cell Viability Testing
            11.4.3.1. Tetrazolium Reduction Assay
            11.4.3.2. Protease Viability Marker Assay
            11.4.3.3. ATP Assay
            11.4.3.4. Real-Time Assay
            11.4.3.5. Others
        11.4.4. Cell Transduction/Transfection
            11.4.4.1. Cationic-lipid Mediated Transfection
            11.4.4.2. Calcium Phosphate Transfection
            11.4.4.3. Viral Transfection
            11.4.4.4. Electroporation
            11.4.4.5. Others
        11.4.5. Cell Expansion
            11.4.5.1. 3D Cell Culture
            11.4.5.2. Roller Bottle Culture
            11.4.5.3. Cell Culture Scale-up Systems
            11.4.5.4. Spinner Flask Culture
            11.4.5.5. Others
        11.4.6. Quality Control Testing
            11.4.6.1. Endotoxin
            11.4.6.2. Mycoplasma
            11.4.6.3. Others
    11.5. Market Value Forecast, by Application, 2017-2031
        11.5.1. Cancer
        11.5.2. Autoimmune Diseases
        11.5.3. Cardiovascular Disorders
        11.5.4. Orthopedic Disorders
        11.5.5. Others
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Cell Type
        11.7.2. By Product
        11.7.3. By Technology/Method
        11.7.4. By Application
        11.7.5. By Country
12. Europe Cell Therapy Technologies Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Cell Type, 2017-2031
        12.2.1. Allogeneic
            12.2.1.1. Blood Cells
            12.2.1.2. Others
        12.2.2. Autologous
            12.2.2.1. Human Embryonic Stem Cells
            12.2.2.2. Hematopoietic Stem Cells
            12.2.2.3. Mesenchymal Stem Cells
            12.2.2.4. Others
    12.3. Market Value Forecast, by Product, 2017-2031
        12.3.1. Tissue Digestion
            12.3.1.1. Instrumentation
            12.3.1.2. Consumables & Reagents
        12.3.2. Cell Selection/ Cell Isolation
            12.3.2.1. Instrumentation
            12.3.2.2. Consumables & Reagents
        12.3.3. Cell Viability Testing
            12.3.3.1. Instrumentation
            12.3.3.2. Consumables & Reagents
        12.3.4. Cell Transduction / Transfection
            12.3.4.1. Instrumentation
            12.3.4.2. Consumables & Reagents
        12.3.5. Cell Expansion
            12.3.5.1. Instrumentation
            12.3.5.2. Consumables & Reagents
        12.3.6. Quality Control Testing
            12.3.6.1. Instrumentation
            12.3.6.2. Consumables & Reagents
    12.4. Market Value Forecast, by Technology/Method, 2017-2031
        12.4.1. Cell Selection/Cell Isolation
            12.4.1.1. Immunomagnetic Cell separation (IMS)
            12.4.1.2. Fluorescence-activated Cell Sorting(FACS)
            12.4.1.3. Density Gradient Centrifugation
            12.4.1.4. Microfluidic Cell Separation (MCS)
            12.4.1.5. Others
        12.4.2. Cell Viability Testing
            12.4.2.1. Tetrazolium Reduction Assay
            12.4.2.2. Protease Viability Marker Assay
            12.4.2.3. ATP Assay
            12.4.2.4. Real-Time Assay
            12.4.2.5. Others
        12.4.3. Cell Transduction/Transfection
            12.4.3.1. Cationic-lipid Mediated Transfection
            12.4.3.2. Calcium Phosphate Transfection
            12.4.3.3. Viral Transfection
            12.4.3.4. Electroporation
            12.4.3.5. Others
        12.4.4. Cell Expansion
            12.4.4.1. 3D Cell Culture
            12.4.4.2. Roller Bottle Culture
            12.4.4.3. Cell Culture Scale-up Systems
            12.4.4.4. Spinner Flask Culture
            12.4.4.5. Others
        12.4.5. Quality Control Testing
            12.4.5.1. Endotoxin
            12.4.5.2. Mycoplasma
            12.4.5.3. Others
    12.5. Market Value Forecast, by Application, 2017-2031
        12.5.1. Cancer
        12.5.2. Autoimmune Diseases
        12.5.3. Cardiovascular Disorders
        12.5.4. Orthopedic Disorders
        12.5.5. Others
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Spain
        12.6.5. Italy
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Cell Type
        12.7.2. By Product
        12.7.3. By Technology/Method
        12.7.4. By Application
        12.7.5. By Country/Sub-region
13. Asia Pacific Cell Therapy Technologies Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Cell Type, 2017-2031
        13.2.1. Allogeneic
            13.2.1.1. Blood Cells
            13.2.1.2. Others
        13.2.2. Autologous
            13.2.2.1. Human Embryonic Stem Cells
            13.2.2.2. Hematopoietic Stem Cells
            13.2.2.3. Mesenchymal Stem Cells
            13.2.2.4. Others
    13.3. Market Value Forecast, by Product, 2017-2031
        13.3.1. Tissue Digestion
            13.3.1.1. Instrumentation
            13.3.1.2. Consumables & Reagents
        13.3.2. Cell Selection/ Cell Isolation
            13.3.2.1. Instrumentation
            13.3.2.2. Consumables & Reagents
        13.3.3. Cell Viability Testing
            13.3.3.1. Instrumentation
            13.3.3.2. Consumables & Reagents
        13.3.4. Cell Transduction / Transfection
            13.3.4.1. Instrumentation
            13.3.4.2. Consumables & Reagents
        13.3.5. Cell Expansion
            13.3.5.1. Instrumentation
            13.3.5.2. Consumables & Reagents
        13.3.6. Quality Control Testing
            13.3.6.1. Instrumentation
            13.3.6.2. Consumables & Reagents
    13.4. Market Value Forecast, by Technology/Method, 2017-2031
        13.4.1. Tissue Digestion
        13.4.2. Cell Selection/Cell Isolation
            13.4.2.1. Immunomagnetic Cell separation (IMS)
            13.4.2.2. Fluorescence-activated Cell Sorting(FACS)
            13.4.2.3. Density Gradient Centrifugation
            13.4.2.4. Microfluidic Cell Separation (MCS)
            13.4.2.5. Others
        13.4.3. Cell Viability Testing
            13.4.3.1. Tetrazolium Reduction Assay
            13.4.3.2. Protease Viability Marker Assay
            13.4.3.3. ATP Assay
            13.4.3.4. Real-Time Assay
            13.4.3.5. Others
        13.4.4. Cell Transduction/Transfection
            13.4.4.1. Cationic-lipid Mediated Transfection
            13.4.4.2. Calcium Phosphate Transfection
            13.4.4.3. Viral Transfection
            13.4.4.4. Electroporation
            13.4.4.5. Others
        13.4.5. Cell Expansion
            13.4.5.1. 3D Cell Culture
            13.4.5.2. Roller Bottle Culture
            13.4.5.3. Cell Culture Scale-up Systems
            13.4.5.4. Spinner Flask Culture
            13.4.5.5. Others
        13.4.6. Quality Control Testing
            13.4.6.1. Endotoxin
            13.4.6.2. Mycoplasma
            13.4.6.3. Others
    13.5. Market Value Forecast, by Application, 2017-2031
        13.5.1. Cancer
        13.5.2. Autoimmune Diseases
        13.5.3. Cardiovascular Disorders
        13.5.4. Orthopedic Disorders
        13.5.5. Others
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Cell Type
        13.7.2. By Product
        13.7.3. By Technology/Method
        13.7.4. By Application
        13.7.5. By Country/Sub-region
14. Latin America Cell Therapy Technologies Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Cell Type, 2017-2031
        14.2.1. Allogeneic
            14.2.1.1. Blood Cells
            14.2.1.2. Others
        14.2.2. Autologous
            14.2.2.1. Human Embryonic Stem Cells
            14.2.2.2. Hematopoietic Stem Cells
            14.2.2.3. Mesenchymal Stem Cells
            14.2.2.4. Others
    14.3. Market Value Forecast, by Product, 2017-2031
        14.3.1. Tissue Digestion
            14.3.1.1. Instrumentation
            14.3.1.2. Consumables & Reagents
        14.3.2. Cell Selection/ Cell Isolation
            14.3.2.1. Instrumentation
            14.3.2.2. Consumables & Reagents
        14.3.3. Cell Viability Testing
            14.3.3.1. Instrumentation
            14.3.3.2. Consumables & Reagents
        14.3.4. Cell Transduction / Transfection
            14.3.4.1. Instrumentation
            14.3.4.2. Consumables & Reagents
        14.3.5. Cell Expansion
            14.3.5.1. Instrumentation
            14.3.5.2. Consumables & Reagents
        14.3.6. Quality Control Testing
            14.3.6.1. Instrumentation
            14.3.6.2. Consumables & Reagents
    14.4. Market Value Forecast, by Technology/Method, 2017-2031
        14.4.1. Tissue Digestion
        14.4.2. Cell Selection/Cell Isolation
            14.4.2.1. Immunomagnetic Cell separation (IMS)
            14.4.2.2. Fluorescence-activated Cell Sorting(FACS)
            14.4.2.3. Density Gradient Centrifugation
            14.4.2.4. Microfluidic Cell Separation (MCS)
            14.4.2.5. Others
        14.4.3. Cell Viability Testing
            14.4.3.1. Tetrazolium Reduction Assay
            14.4.3.2. Protease Viability Marker Assay
            14.4.3.3. ATP Assay
            14.4.3.4. Real-Time Assay
            14.4.3.5. Others
        14.4.4. Cell Transduction/Transfection
            14.4.4.1. Cationic-lipid Mediated Transfection
            14.4.4.2. Calcium Phosphate Transfection
            14.4.4.3. Viral Transfection
            14.4.4.4. Electroporation
            14.4.4.5. Others
        14.4.5. Cell Expansion
            14.4.5.1. 3D Cell Culture
            14.4.5.2. Roller Bottle Culture
            14.4.5.3. Cell Culture Scale-up Systems
            14.4.5.4. Spinner Flask Culture
            14.4.5.5. Others
        14.4.6. Quality Control Testing
            14.4.6.1. Endotoxin
            14.4.6.2. Mycoplasma
            14.4.6.3. Others
    14.5. Market Value Forecast, by Application, 2017-2031
        14.5.1. Cancer
        14.5.2. Autoimmune Diseases
        14.5.3. Cardiovascular Disorders
        14.5.4. Orthopedic Disorders
        14.5.5. Others
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Cell Type
        14.7.2. By Product
        14.7.3. By Technology/Method
        14.7.4. By Application
        14.7.5. By Country/Sub-region
15. Middle East & Africa Cell Therapy Technologies Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Cell Type, 2017-2031
        15.2.1. Allogeneic
            15.2.1.1. Blood Cells
            15.2.1.2. Others
        15.2.2. Autologous
            15.2.2.1. Human Embryonic Stem Cells
            15.2.2.2. Hematopoietic Stem Cells
            15.2.2.3. Mesenchymal Stem Cells
            15.2.2.4. Others
    15.3. Market Value Forecast, by Product, 2017-2031
        15.3.1. Tissue Digestion
            15.3.1.1. Instrumentation
            15.3.1.2. Consumables & Reagents
        15.3.2. Cell Selection/ Cell Isolation
            15.3.2.1. Instrumentation
            15.3.2.2. Consumables & Reagents
        15.3.3. Cell Viability Testing
            15.3.3.1. Instrumentation
            15.3.3.2. Consumables & Reagents
        15.3.4. Cell Transduction / Transfection
            15.3.4.1. Instrumentation
            15.3.4.2. Consumables & Reagents
        15.3.5. Cell Expansion
            15.3.5.1. Instrumentation
            15.3.5.2. Consumables & Reagents
        15.3.6. Quality Control Testing
            15.3.6.1. Instrumentation
            15.3.6.2. Consumables & Reagents
    15.4. Market Value Forecast, by Technology/Method, 2017-2031
        15.4.1. Tissue Digestion
        15.4.2. Cell Selection/Cell Isolation
            15.4.2.1. Immunomagnetic Cell separation (IMS)
            15.4.2.2. Fluorescence-activated Cell Sorting(FACS)
            15.4.2.3. Density Gradient Centrifugation
            15.4.2.4. Microfluidic Cell Separation (MCS)
            15.4.2.5. Others
        15.4.3. Cell Viability Testing
            15.4.3.1. Tetrazolium Reduction Assay
            15.4.3.2. Protease Viability Marker Assay
            15.4.3.3. ATP Assay
            15.4.3.4. Real-Time Assay
            15.4.3.5. Others
        15.4.4. Cell Transduction/Transfection
            15.4.4.1. Cationic-lipid Mediated Transfection
            15.4.4.2. Calcium Phosphate Transfection
            15.4.4.3. Viral Transfection
            15.4.4.4. Electroporation
            15.4.4.5. Others
        15.4.5. Cell Expansion
            15.4.5.1. 3D Cell Culture
            15.4.5.2. Roller Bottle Culture
            15.4.5.3. Cell Culture Scale-up Systems
            15.4.5.4. Spinner Flask Culture
            15.4.5.5. Others
        15.4.6. Quality Control Testing
            15.4.6.1. Endotoxin
            15.4.6.2. Mycoplasma
            15.4.6.3. Others
    15.5. Market Value Forecast, by Application, 2017-2031
        15.5.1. Cancer
        15.5.2. Autoimmune Diseases
        15.5.3. Cardiovascular Disorders
        15.5.4. Orthopedic Disorders
        15.5.5. Others
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Cell Type
        15.7.2. By Product
        15.7.3. By Technology/Method
        15.7.4. By Application
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Share Analysis, by Company, 2022
    16.2. Company Profiles
        16.2.1. Agilent Technologies
            16.2.1.1. Company Overview
            16.2.1.2. Financial Overview
            16.2.1.3. Product Portfolio
            16.2.1.4. Business Strategies
            16.2.1.5. Recent Developments
        16.2.2. Merck KGaA
            16.2.2.1. Company Overview
            16.2.2.2. Financial Overview
            16.2.2.3. Product Portfolio
            16.2.2.4. Business Strategies
            16.2.2.5. Recent Developments
        16.2.3. Thermo Fisher Scientific, Inc.
            16.2.3.1. Company Overview
            16.2.3.2. Financial Overview
            16.2.3.3. Product Portfolio
            16.2.3.4. Business Strategies
            16.2.3.5. Recent Developments
        16.2.4. Miltenyi Biotech
            16.2.4.1. Company Overview
            16.2.4.2. Financial Overview
            16.2.4.3. Product Portfolio
            16.2.4.4. Business Strategies
            16.2.4.5. Recent Developments
        16.2.5. GE Healthcare (General Electric Company)
            16.2.5.1. Company Overview
            16.2.5.2. Financial Overview
            16.2.5.3. Product Portfolio
            16.2.5.4. Business Strategies
            16.2.5.5. Recent Developments
        16.2.6. Beckman Coulter, Inc. (Danaher)
            16.2.6.1. Company Overview
            16.2.6.2. Financial Overview
            16.2.6.3. Product Portfolio
            16.2.6.4. Business Strategies
            16.2.6.5. Recent Developments
        16.2.7. Sartorius AG
            16.2.7.1. Company Overview
            16.2.7.2. Financial Overview
            16.2.7.3. Product Portfolio
            16.2.7.4. Business Strategies
            16.2.7.5. Recent Developments
        16.2.8. Lonza Group
            16.2.8.1. Company Overview
            16.2.8.2. Financial Overview
            16.2.8.3. Product Portfolio
            16.2.8.4. Business Strategies
            16.2.8.5. Recent Developments
        16.2.9. Terumo Corporation
            16.2.9.1. Company Overview
            16.2.9.2. Financial Overview
            16.2.9.3. Product Portfolio
            16.2.9.4. Business Strategies
            16.2.9.5. Recent Developments
        16.2.10. Curate Biosciences
            16.2.10.1. Company Overview
            16.2.10.2. Financial Overview
            16.2.10.3. Product Portfolio
            16.2.10.4. Business Strategies
            16.2.10.5. Recent Developments
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer


-gr.jpg)
 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			